ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1,2,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
2,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
2,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
5,1,Hypertensive encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
6,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
7,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
7,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
8,1,Hypertensive encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
9,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
10,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
11,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
12,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
12,2,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
13,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
13,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
13,3,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
14,1,Hypertensive encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
15,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
16,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
17,1,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
18,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
18,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
19,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
20,1,Dermatitis exfoliative generalised,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
20,2,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
20,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
21,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
21,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
22,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
22,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
23,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
24,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
24,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
24,3,Headache,Headaches NEC,Headaches,Nerv,N
24,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
25,1,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
26,1,Headache,Headaches NEC,Headaches,Nerv,N
26,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
26,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
27,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
27,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
27,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
27,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
28,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
28,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
29,1,Pseudoporphyria,Bullous conditions,Epidermal and dermal conditions,Skin,N
30,1,Pseudoporphyria,Bullous conditions,Epidermal and dermal conditions,Skin,N
31,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
31,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
31,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
32,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
33,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
33,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
34,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
35,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
36,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
37,1,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
38,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
38,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
39,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,Y
39,2,Parvovirus infection,Parvoviral infections,Viral infectious disorders,Infec,N
40,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
40,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
40,3,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
41,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
41,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
42,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
42,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
43,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
43,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
44,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
44,2,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
44,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
45,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
46,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
46,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
47,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
48,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
48,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
49,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
49,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
50,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
50,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
51,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
51,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
52,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
52,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
53,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
53,2,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
54,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
54,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
55,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
55,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
56,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
57,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
57,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
58,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
59,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
60,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
60,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
61,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
61,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
62,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
63,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
63,2,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
63,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
64,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
64,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
65,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
65,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
65,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
66,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
67,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
68,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
69,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
69,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
70,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
70,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
70,3,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
71,1,Hypertensive encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
71,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
72,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
72,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
73,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
74,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
74,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
75,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
76,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
77,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
78,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
78,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
78,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
79,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
80,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
81,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
81,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
81,3,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
82,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
83,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
83,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
83,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
84,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
84,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
85,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
86,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
86,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
86,3,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
86,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
86,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
86,6,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
87,1,Headache,Headaches NEC,Headaches,Nerv,N
87,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
87,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
88,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
88,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
89,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
90,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
90,2,Hypertensive crisis,Accelerated and malignant hypertension,Vascular hypertensive disorders,Vasc,N
90,3,Hypertensive encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
91,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
92,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
92,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
93,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
93,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
94,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
94,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
94,3,Reticulocyte count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
95,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
96,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
96,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
97,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
98,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
99,1,Headache,Headaches NEC,Headaches,Nerv,N
99,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
99,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
100,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
100,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
101,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
102,1,Myelodysplastic syndrome with single lineage dysplasia,Myelodysplastic syndromes,Leukaemias,Neopl,N
103,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
103,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
104,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
104,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
105,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
105,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
106,1,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
106,2,Nail dystrophy,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
106,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
107,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
108,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
109,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
109,2,Reticulocyte count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
110,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
111,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
111,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
112,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
113,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
114,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
114,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
115,1,Splenic rupture,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
116,1,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
117,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
117,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
118,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
118,2,Macrocytosis,Red blood cell abnormal findings NEC,Red blood cell disorders,Blood,N
119,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
120,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
120,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
121,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
122,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
123,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
123,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
124,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
125,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
125,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
126,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
126,2,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
127,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
127,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
127,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
128,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
129,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
129,2,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
129,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
129,4,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
130,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
131,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
131,2,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
131,3,Cardiac failure,Heart failures NEC,Heart failures,Card,N
131,4,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
131,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
131,6,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
132,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
133,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
134,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
134,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
134,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
135,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
136,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
137,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
138,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
139,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
139,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
139,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
140,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
140,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
141,1,Synovitis,Synovial disorders,Synovial and bursal disorders,Musc,N
142,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
142,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
143,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
144,1,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
145,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
146,1,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
147,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
148,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
149,1,Arteriovenous fistula thrombosis,Cardiac and vascular procedural complications,Procedural related injuries and complications NEC,Inj&P,N
150,1,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
151,1,Priapism,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
152,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
152,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
152,3,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
153,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
154,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
154,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
154,3,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
154,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
154,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
155,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
156,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
157,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
158,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
158,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
159,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
159,2,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
159,3,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
160,1,Nipple pain,Breast signs and symptoms,Breast disorders,Repro,N
161,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
162,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
162,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
163,1,Muscle spasticity,Neuromuscular disorders NEC,Neuromuscular disorders,Nerv,N
163,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
164,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
164,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
164,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
165,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
165,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
166,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
166,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
166,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
166,4,Endocarditis,Cardiac infections,Infections - pathogen unspecified,Infec,N
166,5,Meningitis staphylococcal,Staphylococcal infections,Bacterial infectious disorders,Infec,N
166,6,Staphylococcal sepsis,Staphylococcal infections,Bacterial infectious disorders,Infec,Y
167,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
168,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
169,1,Arteriosclerosis coronary artery,Coronary artery disorders NEC,Coronary artery disorders,Card,N
169,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
169,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
169,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
170,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
170,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
170,3,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
171,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
172,1,Myelodysplastic syndrome with excess blasts,Myelodysplastic syndromes,Leukaemias,Neopl,N
173,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
173,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
173,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
173,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
173,5,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
173,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
174,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
175,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,Y
176,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
176,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
177,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
177,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
178,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
179,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
179,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
179,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
179,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
179,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
180,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
180,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
181,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
182,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
182,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
182,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
182,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
182,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
182,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
183,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
184,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
184,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
185,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
186,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
186,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
187,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
187,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
188,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
188,2,Headache,Headaches NEC,Headaches,Nerv,N
188,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
188,4,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
188,5,Papilloedema,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
188,6,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
189,1,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
190,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
191,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
191,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
191,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
191,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
192,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
192,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
193,1,Panniculitis,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
194,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
194,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
194,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
196,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
197,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
198,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
198,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
198,3,Encapsulating peritoneal sclerosis,Peritoneal and retroperitoneal fibrosis and adhesions,Peritoneal and retroperitoneal conditions,Gastr,N
199,1,Salivary gland disorder,Salivary gland disorders NEC,Salivary gland conditions,Gastr,N
200,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
201,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
202,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
202,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
203,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
204,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
204,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
204,3,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
204,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
204,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
204,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
204,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
204,8,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
204,9,Myalgia,Muscle pains,Muscle disorders,Musc,N
204,10,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
205,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
206,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
206,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
207,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
208,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
208,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
208,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
208,4,Myelodysplastic syndrome with single lineage dysplasia,Myelodysplastic syndromes,Leukaemias,Neopl,N
209,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
210,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
211,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
211,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
211,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
212,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
212,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
213,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
214,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
215,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
216,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
216,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
216,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
216,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
216,5,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
216,6,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
216,7,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
216,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
217,1,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
217,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
218,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
218,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
218,3,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
218,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
218,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
219,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
220,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
221,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
221,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
221,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
222,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
223,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
223,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
224,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
225,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
226,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
226,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
227,1,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
228,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
229,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
230,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
231,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
232,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
232,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
232,3,Colorectal adenoma,Lower gastrointestinal neoplasms benign,Gastrointestinal neoplasms benign,Neopl,N
232,4,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
232,5,Klebsiella infection,Klebsiella infections,Bacterial infectious disorders,Infec,N
232,6,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
232,7,Orchitis,Male reproductive tract infections,Infections - pathogen unspecified,Infec,N
232,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
232,9,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
232,10,Urethral stenosis,Structural and obstructive urethral disorders (excl congenital),Urethral disorders (excl calculi),Renal,N
232,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
233,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
233,2,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
233,3,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
234,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
235,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
236,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
237,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
237,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
238,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
238,2,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
238,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
238,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
238,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
239,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
240,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
240,2,Joint noise,Joint related signs and symptoms,Joint disorders,Musc,N
240,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
240,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
241,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
242,1,Angioimmunoblastic T-cell lymphoma,Angioimmunoblastic T-cell lymphomas,Lymphomas non-Hodgkin's T-cell,Neopl,N
243,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
245,1,Headache,Headaches NEC,Headaches,Nerv,N
245,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
245,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
245,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
246,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
247,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
248,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
249,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
249,2,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
249,3,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
249,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
249,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
249,6,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
249,7,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
249,8,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
250,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
250,2,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
250,3,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
251,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
252,1,Blood erythropoietin abnormal,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
252,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
252,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
253,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
254,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
254,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
254,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
255,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
256,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
256,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
256,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
256,4,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
257,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
257,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
258,1,Idiopathic pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
259,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
259,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
259,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,1,Blister infected,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
260,2,Blister infected,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
261,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
261,2,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
261,3,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
261,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
262,1,Anti-erythropoietin antibody,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
263,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
264,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
265,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
265,2,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
265,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
265,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
266,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
266,2,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
266,3,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,Y
267,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
267,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
267,3,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
267,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
267,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
267,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
268,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
269,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
270,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
273,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
274,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
275,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
275,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
275,3,Granulomatosis with polyangiitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
275,4,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
275,5,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
275,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
276,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
277,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
277,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
277,3,Pneumonia streptococcal,Streptococcal infections,Bacterial infectious disorders,Infec,N
277,4,Reticulocyte count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
277,5,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
277,6,Streptococcal bacteraemia,Streptococcal infections,Bacterial infectious disorders,Infec,N
278,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
278,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
279,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
280,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
280,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
281,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
281,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
281,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
281,4,Deafness,Hearing losses,Hearing disorders,Ear,N
281,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
281,6,Excessive cerumen production,External ear disorders NEC,External ear disorders (excl congenital),Ear,N
281,7,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
281,8,Inflammation,Inflammations,General system disorders NEC,Genrl,N
281,9,Rectal discharge,Anal and rectal signs and symptoms,Anal and rectal conditions NEC,Gastr,N
281,10,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
281,11,Skin laceration,Skin injuries NEC,Injuries NEC,Inj&P,N
282,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
282,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
282,3,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
282,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
282,5,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
282,6,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
282,7,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
282,8,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
282,9,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
282,10,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
282,11,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
282,12,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
282,13,Headache,Headaches NEC,Headaches,Nerv,N
282,14,Hiccups,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
282,15,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
282,16,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
282,17,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
282,18,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
282,19,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
282,20,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
282,21,Tendonitis,Tendon disorders,"Tendon, ligament and cartilage disorders",Musc,N
282,22,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
283,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
283,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
283,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
283,4,Renal transplant,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
284,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
284,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
285,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
286,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
287,1,Headache,Headaches NEC,Headaches,Nerv,N
288,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
288,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
289,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
290,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
290,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
290,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
290,4,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
290,5,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
290,6,Renal and pancreas transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
290,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
291,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
291,2,Headache,Headaches NEC,Headaches,Nerv,N
291,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
291,4,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
291,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
292,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
293,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
293,2,Headache,Headaches NEC,Headaches,Nerv,N
293,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
293,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
294,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
294,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
294,3,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
295,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
296,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
296,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
296,3,Intestinal infarction,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,Y
296,4,Intestinal ischaemia,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
296,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
297,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
297,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
297,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
297,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
298,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
298,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
298,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
298,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
298,5,Headache,Headaches NEC,Headaches,Nerv,N
298,6,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
299,1,Anti-erythropoietin antibody,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
299,2,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
300,1,Anti-erythropoietin antibody,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
301,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
302,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
303,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
303,2,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
303,3,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
304,1,Anti-erythropoietin antibody,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
304,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
304,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
304,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
305,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
305,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
306,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
306,2,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
307,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
307,2,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
307,3,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
307,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
307,5,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
308,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
309,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
309,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
310,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
310,2,Drug specific antibody absent,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
310,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
310,4,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,Y
310,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
310,6,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
311,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
312,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
313,1,Retinal vein thrombosis,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
314,1,Hepatoblastoma,Hepatoblastomas,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
315,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
315,2,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
315,3,Fistula,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
315,4,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
316,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
316,2,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
316,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
317,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
318,1,Haemoglobin increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
318,2,Headache,Headaches NEC,Headaches,Nerv,N
318,3,Malignant hypertension,Accelerated and malignant hypertension,Vascular hypertensive disorders,Vasc,N
318,4,Retinopathy hypertensive,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
318,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
319,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
319,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
319,3,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
319,4,Fibula fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
319,5,Renal transplant,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
319,6,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
320,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
320,2,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
321,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
321,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
321,3,Blood erythropoietin,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
321,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
321,5,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
321,6,Myelodysplastic syndrome with single lineage dysplasia,Myelodysplastic syndromes,Leukaemias,Neopl,N
321,7,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
322,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
322,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
323,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
324,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
325,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
326,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
326,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
326,3,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
326,4,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
327,1,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
327,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
327,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
328,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
328,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
328,3,Blood erythropoietin decreased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
328,4,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
329,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
329,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
329,3,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
329,4,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
329,5,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
329,6,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
330,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
331,1,Angiodysplasia,Vascular malformations and acquired anomalies,Vascular disorders NEC,Vasc,N
331,2,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
332,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
332,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
332,3,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
332,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
332,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
333,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
333,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
334,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
334,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
334,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
335,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
335,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
335,3,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
335,4,Mesothelioma malignant,Mesotheliomas malignant and unspecified,Mesotheliomas,Neopl,Y
335,5,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
336,1,Left ventricular failure,Left ventricular failures,Heart failures,Card,N
336,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
337,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
337,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
338,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
338,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
338,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
338,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
339,1,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
339,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
339,3,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
340,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
340,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
341,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
342,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
343,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
343,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
344,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
344,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
344,3,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
344,4,Monoclonal gammopathy,Plasma cell neoplasms NEC,Plasma cell neoplasms,Neopl,N
345,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
346,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
346,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
346,3,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
346,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
346,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
346,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
347,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
347,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
347,3,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
348,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
348,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
348,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
348,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
349,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
350,1,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
351,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
351,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
352,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
352,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
353,1,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,Y
354,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
354,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
355,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
356,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
357,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
357,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
357,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
358,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
358,2,Lymphoplasmacytoid lymphoma/immunocytoma,Lymphoplasmacytoid lymphomas/immunocytomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
358,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
358,4,Schnitzler's syndrome,Urticarias,Angioedema and urticaria,Skin,N
359,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
359,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
359,3,Folate deficiency,Water soluble vitamin deficiencies,Vitamin related disorders,Metab,N
359,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
359,5,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
359,6,Vitamin B12 deficiency,Water soluble vitamin deficiencies,Vitamin related disorders,Metab,N
360,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
360,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
360,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
361,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
362,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
362,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
363,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
363,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
363,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
364,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
365,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
365,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
365,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
366,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
367,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
367,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
368,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
369,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
369,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
369,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
369,4,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
369,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
370,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
371,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
372,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
372,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
372,3,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
372,4,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
372,5,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
372,6,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
373,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
374,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
375,1,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
375,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
375,3,Prostate cancer metastatic,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
376,1,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
376,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
377,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
378,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
378,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
378,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
379,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
380,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
380,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
380,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
381,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
382,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
383,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
383,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
384,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
385,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
386,1,Embolism venous,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
386,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
387,1,Embolism venous,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
387,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
388,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
389,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
389,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
390,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
390,2,Concomitant disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
390,3,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
391,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
392,1,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
393,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
393,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
393,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
393,4,Reticulocyte count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
394,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,Y
395,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
395,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
396,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
397,1,Dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
397,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
398,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
398,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
399,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
399,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
399,3,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
399,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
399,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
400,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
401,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
402,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
403,1,Haemodialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
404,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
404,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
405,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
406,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
407,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
408,1,Anaemia megaloblastic,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
408,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
409,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
409,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
409,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
409,4,Transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
410,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
410,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
411,1,Brain hypoxia,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
411,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
411,3,Device related infection,Infections NEC,Infections - pathogen unspecified,Infec,N
411,4,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
411,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
411,6,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
411,7,Vascular access device culture positive,Microbiology and serology tests NEC,Microbiology and serology investigations,Inv,N
412,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
412,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
412,3,C-reactive protein abnormal,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
412,4,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
412,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
412,6,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
412,7,Limb operation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
412,8,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
412,9,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
412,10,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
412,11,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
413,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
413,2,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
414,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
415,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
415,2,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
416,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
417,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
417,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
417,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
417,4,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
417,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
417,6,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
418,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
418,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
418,3,Salivary hypersecretion,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
418,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
419,1,Fine motor skill dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
419,2,Headache,Headaches NEC,Headaches,Nerv,N
419,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
419,4,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
419,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
419,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
420,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
420,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
421,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
422,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
422,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
423,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
424,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
424,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
424,3,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
425,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
426,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
426,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
426,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
426,4,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
426,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
427,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
428,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
429,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
430,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
431,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
431,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
431,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
431,4,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
432,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
432,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
433,1,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
433,2,Listless,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
433,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
434,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
434,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
434,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
435,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
436,1,Blood pressure abnormal,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
437,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
438,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
439,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
439,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
439,3,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
440,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
441,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
442,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
442,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
442,3,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
442,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
442,5,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
443,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
444,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
445,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
446,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
446,2,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
446,3,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
446,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
446,5,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
447,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
448,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
449,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
449,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
449,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
450,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
451,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
452,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
453,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
454,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
455,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
456,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
457,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
457,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
457,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
457,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
457,5,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
457,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
458,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
458,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
458,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
458,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
459,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
460,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
461,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
462,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
463,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
463,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
463,3,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
463,4,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
464,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
465,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
466,1,Haemoglobin increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
467,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
468,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
469,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
469,2,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
470,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
470,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
470,3,Reticulocyte count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
470,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
471,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
472,1,Crying,General signs and symptoms NEC,General system disorders NEC,Genrl,N
472,2,Stool pH decreased,Faecal analyses NEC,Gastrointestinal investigations,Inv,N
473,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
474,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
474,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
474,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
474,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
475,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
476,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
477,1,Back injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
477,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
478,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
478,2,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
479,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
480,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
481,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
482,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
483,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
484,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
485,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
485,2,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
485,3,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
485,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
486,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
486,2,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
486,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
486,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
487,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
488,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
488,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
488,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
488,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
489,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
490,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
491,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
491,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
491,3,Headache,Headaches NEC,Headaches,Nerv,N
492,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
492,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
492,3,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
492,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
493,1,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
494,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
495,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
496,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
497,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
498,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
499,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
499,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
499,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
499,4,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
499,5,Stab wound,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
500,1,Anal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
500,2,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
500,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
500,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
501,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
502,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
503,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
503,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
503,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
504,1,Dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
505,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
505,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
506,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
506,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
507,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
508,1,Haemodialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
509,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
510,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
511,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
511,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
511,3,Campylobacter gastroenteritis,Campylobacter infections,Bacterial infectious disorders,Infec,N
511,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
511,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
511,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
512,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
513,1,Bacteraemia,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
513,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
514,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
514,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
515,1,Haemodialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,Y
516,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
517,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
517,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
517,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
517,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
518,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
519,1,Injury associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
519,2,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
520,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
520,2,Anti-erythropoietin antibody,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
520,3,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
520,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
520,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
521,1,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
522,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
523,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
524,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
525,1,Clavicle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
526,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
526,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
526,3,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
527,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
528,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
529,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
530,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
531,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
532,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
533,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
534,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
535,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
536,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
537,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
538,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
538,2,Transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
539,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
540,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
541,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
542,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
542,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
543,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
543,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
544,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
544,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
545,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
545,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
545,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
545,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
546,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
547,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
548,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
549,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
549,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
550,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
550,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
550,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
551,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
551,2,Hypertrophy,Trophic disorders,Tissue disorders NEC,Genrl,N
551,3,Liver iron concentration increased,Hepatobiliary histopathology procedures,Hepatobiliary investigations,Inv,N
551,4,Monocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
551,5,Paroxysmal nocturnal haemoglobinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
551,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
551,7,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
551,8,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
551,9,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
552,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
553,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
553,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
553,3,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,Y
554,1,Auditory disorder,Hearing disorders NEC,Hearing disorders,Ear,N
554,2,Oxycorticosteroids increased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
555,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
556,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
556,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
556,3,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
556,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
557,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
557,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
558,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
559,1,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
560,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
560,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
561,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
561,2,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
562,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
563,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
563,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
563,3,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
563,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
564,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
564,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
565,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
566,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
567,1,Abdominal hernia,Abdominal hernias NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
567,2,Cleft palate,Palate disorders congenital,Gastrointestinal tract disorders congenital,Cong,N
567,3,Coarctation of the aorta,Great vessel disorders congenital,Cardiac and vascular disorders congenital,Cong,N
567,4,Congenital anomaly,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
567,5,Congenital diaphragmatic hernia,Diaphragmatic disorders congenital,Respiratory disorders congenital,Cong,N
567,6,Congenital nail disorder,Hair and nail disorders congenital,Skin and subcutaneous tissue disorders congenital,Cong,N
567,7,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
567,8,Dysmorphism,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
567,9,Fryns syndrome,Autosomal chromosomal abnormalities,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
567,10,Heart disease congenital,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
567,11,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
567,12,Microtia,External ear disorders congenital,Ear and labyrinthine disorders congenital,Cong,N
567,13,Oesophageal atresia,Oesophageal disorders congenital,Gastrointestinal tract disorders congenital,Cong,N
567,14,Pulmonary hypoplasia,Pulmonary and bronchial disorders congenital,Respiratory disorders congenital,Cong,Y
567,15,Tracheo-oesophageal fistula,Laryngeal and tracheal disorders congenital,Respiratory disorders congenital,Cong,N
568,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
569,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
569,2,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
569,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
570,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
571,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
571,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
571,3,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
572,1,Anti-erythropoietin antibody,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
572,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
573,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
573,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
573,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
574,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
574,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
575,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
576,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
576,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
576,3,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
577,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
577,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
577,3,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
577,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
577,5,Blood creatine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
577,6,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
577,7,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
577,8,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
577,9,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
577,10,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
577,11,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
577,12,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
577,13,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
577,14,Headache,Headaches NEC,Headaches,Nerv,N
577,15,Hiccups,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
577,16,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
577,17,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
577,18,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
577,19,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
577,20,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
577,21,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
577,22,Tendonitis,Tendon disorders,"Tendon, ligament and cartilage disorders",Musc,N
577,23,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
578,1,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
579,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
580,1,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
581,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
581,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
582,1,Anti-erythropoietin antibody,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
583,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
583,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
584,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
584,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
584,3,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
584,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
585,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
586,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
587,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
588,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
588,2,Joint effusion,Joint related signs and symptoms,Joint disorders,Musc,N
589,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
590,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
591,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
592,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
593,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
594,1,Blood parathyroid hormone increased,Parathyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
594,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
595,1,Kaposi's sarcoma,Kaposi's sarcomas,Soft tissue neoplasms malignant and unspecified,Neopl,N
596,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
596,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
596,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
597,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
598,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
598,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
598,3,Dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
598,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
599,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
600,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
601,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
601,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
602,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
602,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
602,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
603,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
604,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
604,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
604,3,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
604,4,Proctitis,Rectal inflammations NEC,Gastrointestinal inflammatory conditions,Gastr,N
604,5,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
605,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
606,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
607,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
607,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
608,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
608,2,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
609,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
609,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
610,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
610,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
610,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
611,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
612,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
612,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
613,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
614,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
615,1,Antibody test,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
615,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
616,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
617,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
618,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
618,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
619,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
619,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
619,3,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
620,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
620,2,Hypervolaemia,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
620,3,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
621,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
622,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
622,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
623,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
623,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
623,3,Folate deficiency,Water soluble vitamin deficiencies,Vitamin related disorders,Metab,N
623,4,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
624,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
625,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
625,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
625,3,Folate deficiency,Water soluble vitamin deficiencies,Vitamin related disorders,Metab,N
625,4,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
626,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
626,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
627,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
627,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
628,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
628,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
629,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
629,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
629,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
629,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
629,5,Plasma cell myeloma recurrent,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
630,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
631,1,Eyelid bleeding,Lid bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
631,2,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
631,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
632,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
633,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
633,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
633,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
634,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
635,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
636,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
637,1,Haematocrit,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
637,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
638,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
639,1,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
639,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
640,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
640,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
640,3,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
641,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
642,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
643,1,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
643,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
643,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
644,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
644,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
644,3,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
644,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
644,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
644,6,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
644,7,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
644,8,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
644,9,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
644,10,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
644,11,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
644,12,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
644,13,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
644,14,Neutrophil count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
644,15,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
644,16,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
645,1,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
645,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
645,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
645,4,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
645,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
646,1,Papilloedema,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
646,2,Post transplant lymphoproliferative disorder,Lymphoproliferative disorders NEC (excl leukaemias and lymphomas),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
647,1,Epstein-Barr virus infection,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
647,2,Post transplant lymphoproliferative disorder,Lymphoproliferative disorders NEC (excl leukaemias and lymphomas),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
648,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
649,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
650,1,Papilloedema,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
650,2,Post transplant lymphoproliferative disorder,Lymphoproliferative disorders NEC (excl leukaemias and lymphomas),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
651,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
651,2,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
652,1,Radiotherapy,Radiotherapies site unspecified,Therapeutic procedures and supportive care NEC,Surg,N
653,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
654,1,Hypercoagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
655,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
656,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
657,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
657,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
658,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
658,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
658,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
659,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
659,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
659,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
659,4,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
660,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
661,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
661,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
662,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
662,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
663,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
664,1,Renal transplant,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
665,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
666,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
667,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
668,1,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
668,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
669,1,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
670,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
671,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
672,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
672,2,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
672,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
672,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
673,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
674,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
674,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
674,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
675,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
675,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
675,3,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
675,4,IgA nephropathy,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
675,5,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
675,6,Neutralising antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
676,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
677,1,Haemoglobin increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
678,1,Haemoglobin increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
679,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
680,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
681,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
682,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
682,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
683,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
684,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
684,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
685,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
686,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
686,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
687,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
688,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
689,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
689,2,Device use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
690,1,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
691,1,Deafness,Hearing losses,Hearing disorders,Ear,N
691,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
692,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
692,2,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
693,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
694,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
695,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
695,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
696,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
696,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
697,1,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
698,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
699,1,Spleen disorder,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
700,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
701,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
702,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
703,1,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
704,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
705,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
706,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
707,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
708,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
709,1,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
710,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
710,2,Palliative care,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
711,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
711,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
711,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
711,4,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
711,5,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
712,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
712,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
713,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
713,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
713,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
714,1,Ischaemia,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
714,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
715,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
715,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
716,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
717,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
718,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
719,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
719,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
720,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
720,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
721,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
721,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
721,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
721,4,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
721,5,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
722,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
722,2,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
722,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
722,4,Folate deficiency,Water soluble vitamin deficiencies,Vitamin related disorders,Metab,N
722,5,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
722,6,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
723,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
723,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
723,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
723,4,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
723,5,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
723,6,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
724,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
724,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
725,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
725,2,Urethral cancer,Urinary tract neoplasms malignant NEC,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
726,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
727,1,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
728,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
729,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
729,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
729,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
730,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
731,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
731,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
731,3,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
732,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
732,2,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
732,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
733,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
734,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
734,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
735,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
735,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
736,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
736,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
736,3,Osteorrhagia,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
737,1,Death,Death and sudden death,Fatal outcomes,Genrl,N
738,1,Anti-erythropoietin antibody negative,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
738,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
738,3,Hyperparathyroidism,Hyperparathyroid disorders,Parathyroid gland disorders,Endo,N
738,4,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
738,5,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
739,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
740,1,Blood pressure measurement,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
741,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
742,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
742,2,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
743,1,Blood pressure diastolic decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
743,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
744,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
744,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
744,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
745,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
